Should You Buy Neogenomics Inc (NEO) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
NEO is not a good buy right now for an impatient investor looking for an immediate edge. The near-term technicals are weak (bearish MACD expansion, RSI below 40) and there are no Intellectia buy signals to override that. If you want to get involved soon, the better “right-now” trigger is a reclaim above ~12.66 (pivot) or a clean bounce that holds 12.18 support; at the current pre-market ~12.20, the setup still looks like it can slip into the 11.88–12.18 support zone first.
Technical Analysis
Trend/price action: Pre-market ~12.20 (-1.61%) with the market also risk-off (S&P 500 -0.69%), adding short-term pressure.
Momentum: MACD histogram is negative (-0.0968) and expanding lower → bearish momentum is strengthening.
RSI: RSI(6) ~39.2 → not “oversold enough” to signal a high-conviction snapback; more consistent with a weak/soft tape.
Moving averages: Converging MAs → no clear uptrend; price is in a decision zone where momentum is currently tilting down.
Key levels: Support S1 ~12.179 (price is sitting right on it pre-market), then S2 ~11.884. Resistance/pivot ~12.657, then R1 ~13.134.
Pattern-based forward view: Similar-pattern stats show slightly negative skew next day/week (-0.31% / -0.62%) with a modest positive 1-month bias (+2.28%), suggesting any buy is more appealing on weakness/support confirmation than chasing now.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Analyst Ratings and Price Target Trends
Recent changes show a modestly improving Street stance:
- TD Cowen (2026-01-07): Buy, PT raised to $16 (from $14) → most constructive view in the set.
- BofA (2025-12-15): Neutral, PT raised to $13 (from $11) → improving outlook but not a full endorsement.
- Piper Sandler (2025-11-10): Overweight, PT raised to $12 (from $11) → positive but closer to current trading levels.
Wall Street pros: improving targets, expectation of solid sector fundamentals/normalization into 2026, and company growth.
Wall Street cons: not unanimous (Neutral at BofA), and near-term execution/margin trends remain key.
Influential/political trading: No recent congress trading data available; hedge funds/insiders flagged as neutral with no significant recent trend.
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 14 USD with a low forecast of 12 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 14 USD with a low forecast of 12 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 12.380
Current: 12.380
